Switch theme
Sign up to access all valuation multiples
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.
2010
n/a
LTM Revenue n/a
LTM EBITDA n/a
$141M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Turk İlaç has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Turk İlaç achieved revenue of $67.5M and an EBITDA of $20.4M.
Turk İlaç expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Turk İlaç valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $50.3M | $67.5M | XXX | XXX | XXX |
| Gross Profit | $5.5M | $11.3M | XXX | XXX | XXX |
| Gross Margin | 11% | 17% | XXX | XXX | XXX |
| EBITDA | $7.5M | $20.4M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 30% | XXX | XXX | XXX |
| Net Profit | $1.7M | $2.8M | XXX | XXX | XXX |
| Net Margin | 3% | 4% | XXX | XXX | XXX |
| Net Debt | $6.9M | $10.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Turk İlaç's stock price is TRY 23 (or $1).
Turk İlaç has current market cap of TRY 3.7B (or $97.8M), and EV of TRY 5.4B (or $141M).
See Turk İlaç trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $141M | $97.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Turk İlaç has market cap of $97.8M and EV of $141M.
Turk İlaç's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Turk İlaç's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Turk İlaç and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $141M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 6.9x | XXX | XXX | XXX |
| P/E | 51.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTurk İlaç's NTM/LTM revenue growth is n/a
Turk İlaç's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Turk İlaç's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Turk İlaç's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Turk İlaç and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 170% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 10% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Turk İlaç acquired XXX companies to date.
Last acquisition by Turk İlaç was XXXXXXXX, XXXXX XXXXX XXXXXX . Turk İlaç acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Turk İlaç founded? | Turk İlaç was founded in 2010. |
| Where is Turk İlaç headquartered? | Turk İlaç is headquartered in Turkey. |
| Is Turk İlaç publicy listed? | Yes, Turk İlaç is a public company listed on IST. |
| What is the stock symbol of Turk İlaç? | Turk İlaç trades under TRILC ticker. |
| When did Turk İlaç go public? | Turk İlaç went public in 2021. |
| Who are competitors of Turk İlaç? | Similar companies to Turk İlaç include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Turk İlaç? | Turk İlaç's current market cap is $97.8M |
| What is the current revenue growth of Turk İlaç? | Turk İlaç revenue growth between 2023 and 2024 was 34%. |
| Is Turk İlaç profitable? | Yes, Turk İlaç is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
